19:50 , Jun 17, 2019 |  BC Innovations  |  Distillery Therapeutics

Scorpion venom-derived benzoquinones could treat Staphylococcus and tuberculosis infections

DISEASE CATEGORY: Infectious disease INDICATION: Staphylococcus, tuberculosis Two benzoquinone derivatives derived from scorpion venom could help treat Staphylococcus aureus and Mycobacterium tuberculosis infections. Bacterial growth assays showed the derivatives inhibited growth of an S. aureus...
19:49 , Jun 7, 2019 |  BioCentury  |  Emerging Company Profile

insitro: machine learning with designated data

Just 12 months after announcing the launch of insitro, AI veteran and CEO Daphne Koller has led the drug discovery and machine learning company to a series A round of over $100 million and a...
23:02 , May 30, 2019 |  BC Innovations  |  Product Development

CAR T developers plan steps to reach more indications

As CAR T developers take stock after the first wave of approvals, they are drawing a to-do list of what changes are needed to broaden the modality from its narrow indications and fully exploit its...
17:54 , May 28, 2019 |  BC Innovations  |  Distillery Therapeutics

Synthetic fusion protein system for EGFR- and HER2-positive cancers

DISEASE CATEGORY: Cancer INDICATION: Breast cancer; brain cancer; non-small cell lung cancer (NSCLC); pancreatic cancer In vitro studies suggest a synthetic fusion protein-based system could help treat EGFR- or HER2-positive cancers. The system consists of...
22:17 , May 24, 2019 |  BC Extra  |  Preclinical News

May 24 Preclinical Quick Takes: Baker-Garcia team controls cytokine receptor signaling; plus data from Surface, Innate, Moderna and Lyvgen

Cytokine mimics permit control of dimer receptor signaling  David Baker and Christopher Garcia's University of Washington-Stanford University team has created cytokine mimetics -- symmetric compounds for tunable control of cytokine receptor signaling. In a proof-of-concept...
20:49 , May 24, 2019 |  BioCentury  |  Finance

How Europe’s hotspots of innovation could fuel its rise as a global player in new modalities

It is clear that Europe has hotspots of innovation that are discovering and developing the next wave of new therapeutic modalities. Nearly every category of new modality has a European champion, with clusters forming around...
20:45 , May 24, 2019 |  BioCentury  |  Finance

Europe: Some spots hotter than others

Led by the U.K., various regions in Europe are raising their profile as hotspots of innovation. But as other areas lose ground, local VCs are raising fresh capital and building the infrastructure needed to boost...
21:31 , May 23, 2019 |  BC Innovations  |  Translation in Brief

Synthetic biology redirects oncogenic signaling against cancer

Stanford scientists have used synthetic biology to turn cancer cell signaling against tumors by harnessing EGF receptor signaling instead of inhibiting it, and might spin out a company to develop the technology. The Stanford University...
21:08 , May 23, 2019 |  BC Innovations  |  Emerging Company Profile

Obsidian: Fine-tuning therapeutic protein expression with approved drugs

Obsidian is building a tool kit of engineered proteins whose expression can be finely tuned with FDA-approved small molecules, and its first application is in boosting the efficacy of cell therapies through a deal with...
23:24 , May 15, 2019 |  BC Extra  |  Company News

Management tracks: Biogen’s McKenzie departing for CSL; plus Rubius, SanBio, Avita and more

Paul McKenzie is leaving Biogen Inc. (NASDAQ:BIIB) as EVP, pharmaceutical operations & technology to become COO of CSL Ltd. (ASX:CSL). A veteran of Johnson & Johnson (NYSE:JNJ), Bristol-Myers Squibb Co. (NYSE:BMY) and Merck & Co....